A Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 Cells in Severe Coronavirus Disease 2019 Patients
A Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 Cells in Severe Coronavirus Disease 2019 Patients is a PHASE1 clinical asset sponsored by LucasBio in COVID-19, COVID-19 (SARS-CoV-2 Infection). SEO and diligence focus: LB-DTK-COV19, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: COVID-19
Modality: cell therapy
Target: LB-DTK-COV19
Sponsor: LucasBio
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: LB-DTK-COV19
View original source fields
Condition raw: COVID-19, COVID-19 (SARS-CoV-2 Infection)
Condition normalized: COVID-19, COVID-19 (SARS-CoV-2 Infection)
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: LB-DTK-COV19
Target normalized: LB-DTK-COV19